Nuformix plc (LON:NFX – Get Free Report) shares fell 11.1% during trading on Wednesday . The stock traded as low as GBX 0.08 ($0.00) and last traded at GBX 0.08 ($0.00). 13,393,661 shares changed hands during trading, a decline of 78% from the average session volume of 62,280,551 shares. The stock had previously closed at GBX 0.09 ($0.00).
Nuformix Stock Performance
The business has a 50-day simple moving average of GBX 0.07 and a two-hundred day simple moving average of GBX 0.08. The company has a market capitalization of £985,447.27, a price-to-earnings ratio of -2.43 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- Insider Trades May Not Tell You What You Think
- Lemonade’s Q4 Surge: Has This AI-Powered Insurer Turned a Corner?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- 2 Energy Stocks to Play Both Sides of Tariff Uncertainty
- Insider Buying Explained: What Investors Need to Know
- Raytheon vs. Lockheed Martin: Which Stock Has More Upside?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
